Shake-Up at FDA: Uncertainty as Key Leader Departs

Tracy Beth Hoeg, the acting head of the FDA's drug center, is expected to leave the agency amidst internal changes and a broader health department shake-up. Hoeg played a significant role in proposed changes to the U.S. childhood vaccination schedule, now on hold due to a lawsuit involving Health Secretary Robert F. Kennedy.

Tracy Beth Hoeg, currently serving as the acting head of the U.S. Food and Drug Administration's drug center, is reportedly on her way out of the agency. Sources familiar with internal plans disclosed this expected departure follows the recent resignation of Commissioner Marty Makary, creating a leadership vacuum at a critical time.

Hoeg, an epidemiologist and sports physician, raised eyebrows when she questioned the efficacy of COVID vaccines during the pandemic. In January, she spearheaded efforts to streamline the U.S. childhood vaccination schedule, slashing recommended shots from 17 to 11. However, these changes hit a roadblock due to a lawsuit over vaccine policy revisions led by Health Secretary Robert F. Kennedy.

The Health and Human Services (HHS) department has refrained from commenting on Hoeg's expected exit, stating personnel matters remain confidential. Meanwhile, the White House has taken steps to reinforce control over the health department as the Biden administration braces for potential voter backlash from Kennedy's controversial vaccine policy overhaul during the upcoming midterm elections.